Liquidia Technologies, a clinical stage biotech developing dry powder therapies for pulmonary arterial hypertension, filed on Thursday with the SEC to raise up to $58 million in an initial public offering.
The Morrisville, NC-based company was founded in 2004 and booked $7 million in revenue for the 12 months ended March 31, 2018. It plans to list on the Nasdaq under the symbol LQDA. Liquidia Technologies filed confidentially on February 5, 2018. Jefferies and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
